In 29 patients undergoing percutaneous coronary intervention (PCI), we obtained blood samples at baseline, 10 minutes after standard weight-based abciximab (n=15) or double-bolus eptifibatide (n=14) and 5 minutes after unfractionated heparin (UFH; 70 U/kg bolus). The median percent inhibition was significantly higher in the eptifibatide group compared with the abciximab group both before (96.5% [94-100] vs. 85% [77-89.5] [adenosine diphosphate; ADP]; 89.5% [84-95] vs. 59% [37.5-76.5] [thrombin receptor agonist peptide; TRAP], p<0.001 for both) and after UFH (95% [93-100] vs. 79% [68.8-87.5] [ADP]; 82% [77-93] vs. 51% [34.5-71.3] [TRAP], p<0.001 for both). Addition of UFH significantly reduced platelet inhibition in the abciximab group (85% [77-89.5] vs. 79% [68.8-87.5] [ADP]; 59% [37.5-76.5] vs. 51% [34.5-71.3] [TRAP], p<0.05 for both) but not in the eptifibatide group (96.5% [94-100] vs. 95% [93-100] [ADP]; 89.5% [84-95] vs. 82% [77-93] [TRAP], p=ns for both). Eptifibatide achieved superior platelet inhibition before but especially after UFH compared with abciximab.

译文

在29例接受经皮冠状动脉介入治疗 (PCI) 的患者中,我们在基线,基于标准体重的阿昔单抗 (n = 15) 或双推注eptifibatide (n = 14) 后10分钟和普通肝素 (UFH; 70 U/kg推注) 后5分钟获得了血液样本。与阿昔单抗组相比,依替巴肽组的中位抑制百分比均显着更高 (96.5% [94-100] vs. 85% [77-89.5] [二磷酸腺苷; ADP]; 89.5% [84-95] vs. 59% [37.5-76.5] [凝血酶受体激动剂肽; TRAP],p<0.001) 和UFH之后 (95% [93-100] 对79% [68.8-87.5] [ADP]; 82% [77-93] 对51% [34.5-71.3] [TRAP],p<0.001)。添加UFH可显着降低阿昔单抗组的血小板抑制作用 (85% [77-89.5] vs. 79% [68.8-87.5] [ADP]; 59% [37.5-76.5] vs. 51% [34.5-71.3] [TRAP],p<0.05),但在依替巴肽组中没有 (96.5% [94-100] 对95% [93-100] [ADP]; 89.5% [84-95] 对82% [77-93] [TRAP],p = ns)。与阿昔单抗相比,依替非巴肽在UFH之前 (尤其是在UFH之后) 获得了更好的血小板抑制作用。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录